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Abstract Inhibitory and excitatory synapses play a funda-
mental role in information processing in the brain.
Excitatory synapses usually are situated on dendritic spines,
small membrane protrusions that harbor glutamate receptors
and postsynaptic density components and help transmit
electrical signals. In recent years, it has become evident that
spine morphology is intimately linked to synapse function—
smaller spines have smaller synapses and support reduced
synaptic transmission. The relationship between synaptic
signaling, spine shape, and brain function is never more
apparent than when the brain becomes dysfunctional. Many
psychiatric and neurologic disorders, ranging from mental
retardation and autism to Alzheimer’s disease and addiction,
are accompanied by alterations in spine morphology and
synapse number. In this review, we highlight the structure and
molecular organization of synapses and discuss functional
effects of synapse pathology in brain disease.
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Introduction
The brain is the center of the nervous system and the most
complex biological structure known. All thoughts, emotions,
memories, behaviors, dreams, and other aspects of cognition
arise within the brain. The brain coordinates the abilities to
move, touch, smell, taste, hear, and see. It enables people to
form words, understand mathematics, communicate with
others, make decisions, compose and appreciate music, plan
ahead, and even fantasize. It comes as no surprise that
alterations in brain function account for many, if not most,
neurologic and psychiatric disorders.
The human brain consists of more than 1011 (100 billion)
neurons, which process and transmit information in the
form of electrical signals. Communication between neurons
occurs at specialized junctions called synapses. During
the past century, basic neuroscience has taught us a great
deal about the molecular and cellular mechanisms of
synapse formation, stability, and function. Precise control
of synaptic development and connectivity is critical for
maintaining accurate neuronal network activity and normal
brain function. Now it is widely believed that information
in the brain can be stored in the form of altered structure
and chemistry of synapses and/or by the formation of new
synapses and the elimination of old ones [1]. This so-called
plasticity of synapses is believed to be the basis of learning
and memory in the brain.
It is not surprising that the inappropriate loss of synaptic
stability may lead to the disruption of neuronal circuits and
to brain diseases. Whether as the result of genetics, drug
use, the aging process, viral infections, or other various
causes, dysfunction in neuronal communication is almost
certainly the underlying cause of many psychiatric and
neurologic diseases, such as mental retardation [2], schizo-
phrenia [3], Parkinson’s disease [4], autism [5], Alzheimer’s
disease (AD) [6], compulsive behavior [7], and addiction [8].
Recent studies show that many neuropsychiatric diseases are
characterized by synaptic pathology—including abnormal
density and morphology of dendritic spines, synapse loss,
and aberrant synaptic signaling and plasticity [9]. For AD,
synaptic loss is the best current pathologic correlate of
cognitive decline, and synaptic dysfunction is evident long
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before synapses and neurons are lost. The synapse thus
constitutes an important target for treatments to slow
progression and preserve cognitive and functional abilities
in the disease. Understanding brain disorders is, at least in
part, a matter of understanding the biochemical and cell
biological basis of synaptic function and plasticity.
In this review, we discuss recent evidence that alteration
in synapse structure and function underlies several psychi-
atric and neurologic disorders. We describe our current
understanding of the molecular organization of excitatory
and inhibitory synapses and propose that basic cell biological
mechanisms link synapse function with neuropsychiatric
health and disease.
Microanatomy of the Synapses
Chemical synapses consist of presynaptic axon terminals
harboring synaptic vesicles and a postsynaptic region
(usually on dendrites) containing neurotransmitter receptors
(Fig. 1). The pre- and postsynaptic sites are separated by a
gap of 20 to 25 nm, the synaptic cleft [10, 11]. A wide variety
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Fig. 1 Molecular architecture of inhibitory and excitatory synapses.
The top panels show excitatory and inhibitory synapses. Excitatory
synapses target on mature mushroom-shaped spines containing a
prominent postsynaptic density (PSD), and inhibitory synapses are
present along the dendritic shaft lacking postsynaptic thickening.
Various organelles support the synapse; mitochondria provide energy,
polyribosomes and RNA particles allow local protein synthesis,
recycling endosomes (REs) transport internalized synaptic receptors
back to the plasma membrane, and the cytoskeleton regulates spine
dynamics. The abundant actin cytoskeleton is connected to the PSD
and is the primary determinant of spine shape and motility. Transient
invasion of dynamic microtubule into dendritic spines can regulate
formation of spine head protrusions and rapid spine growth.
Excitatory and inhibitory synapses contain a unique set of channels,
scaffolding proteins, and other postsynaptic molecules. The microanat-
omy of the inhibitory and excitatory synapses and their organization of
proteins and protein–protein interactions are depicted in the left and right
panels, respectively. Major families of postsynaptic proteins are shown,
including scaffolding proteins, adhesion molecules, and receptors. The
lower panel shows major morphologic events occurring in dendritic
spines upon long-term potentiation (LTP; left) or long-term depression
(LTD; right). In Alzheimer’s disease and mental retardation, signaling
cascades are triggered similar to LTD, leading to thinner, immature
spines. In contrast, cocaine addiction shows similarities to LTP, resulting
in bigger, mushroom-shaped, mature spines. The molecular and
morphologic changes in the synapse are hallmarks of the disease
pathology and are responsible for the cognitive alterations in neuropsy-
chiatric diseases. CamKII—Ca2+/calmodulin-dependent kinase II;
AMPAR—amino-3-hydroxy-5-methyl-4-isoazolepropionate receptor;
GABA—γ-aminobutyric acid; GABAR—GABA receptor; NMDAR—N-
methyl-D-aspartate receptor; mGluR—metabotropic glutamate receptor;
SAPAP—synapse-associated protein 90/PSD-95-associated protein
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of cell adhesion molecules hold pre- and postsynaptic
membranes together at the appropriate separation. Recently,
several cell adhesion molecules, including N-cadherin, have
been implicated in synapse formation and function [12, 13].
In humans, alterations in genes encoding the cell adhesion
molecules neuroligin (NLGN) and neurexin (NRXN) recently
were implicated in autism, directly linking synaptic proteins to
cognition and its disorders [5].
Presynaptic Structure and Function
The nerve impulse, or action potential, traveling along
the axonal membrane of the presynaptic neuron cannot
cross the synaptic cleft to communicate with postsynaptic
neurons. Therefore, the electric signal is carried at the
synapse by neurotransmitters, such as glutamate or γ-
aminobutyric acid (GABA). These neurotransmitters are
made by the presynaptic neuron and stored in synaptic
vesicles at presynaptic terminals (Fig. 1). Synaptic vesicles
make contact with a thickening of the presynaptic plasma
membrane, named the active zone, where vesicle fusion and
exocytosis of neurotransmitters occur [14]. Genetic and
biochemical studies from mice, Caenorhabditis elegans,
and Drosophila have identified numerous proteins involved
in controlling synaptic vesicle fusion and neurotransmitter
release [15]. The docking and fusion of vesicles at the
presynaptic membrane is at least controlled by the soluble N-
ethylmaleimide–sensitive factor attachment protein receptor
(SNARE) complex [14]. Many other presynaptic proteins
bind to SNAREs and regulate the formation or disassembly
of this complex, whereas others control Ca2+-dependent
neurotransmitter release [15]. Other studies show a critical
role for presynaptic molecules in the pathology of neurode-
generative disease. For example, the presynaptic protein α-
synuclein is involved in the pathogenesis of Parkinson’s
disease [16].
Postsynaptic Structure and Function
Neurotransmitters released from the presynaptic terminal
act on neurotransmitter receptors on the membrane of the
postsynaptic neuron. Whether a synapse is excitatory or
inhibitory determines the postsynaptic current displayed,
which in turn is a function of the type of receptors and
neurotransmitters operating at the synapse (Fig. 1). There
are two types of postsynaptic receptors that recognize
neurotransmitters: ligand-gated ion channels (ionotropic
receptors) and G protein-coupled (metabotropic) receptors.
The binding of glutamate to amino-3-hydroxy-5-methyl-4-
isoazolepropionate (AMPA)-type and N-methyl-D-aspartate
(NMDA)-type ionotropic glutamate receptors leads to excit-
atory synaptic transmission [17], whereas the interaction of
GABA and ionotropic GABAA receptors allows an influx of
negatively charged chloride ions and provides the major
form of inhibitory synaptic transmission [18]. Recently, the
architecture and atomic structure of the ionotropic glutamate
receptor were resolved [19].
Neuronal signal processing is mediated by integration of
excitatory and inhibitory synaptic inputs. A single neuron
usually has hundreds or thousands of excitatory and
inhibitory synapses at its dendrites or cell body, and
whether this neuron fires an action potential depends on
the total input of all these synapses. If the postsynaptic
neuron receives many strong inhibitory synaptic inputs, the
likelihood of the cell firing an action potential is very low.
Therefore, precise regulatory mechanisms must exist to
maintain the balance of excitatory and inhibitory synaptic
transmission, the so-called E/I balance. Alteration in the
E/I synapse balance has been proposed for many brain
disorders, including autism and schizophrenia [5, 18].
Immediately behind the postsynaptic membrane is an
elaborate complex of interlinked proteins called the postsyn-
aptic density (PSD), in which adhesion molecules, receptors,
and their associated signaling proteins are highly concentrated
(Fig. 1). The presence of a prominent PSD is characteristic of
excitatory synapses; in contrast, inhibitory synapses lack
postsynaptic thickening [10, 11]. The PSD is identified by
electron microscopy as electron-dense material approximately
20 to 30 nm thick and around 300 nm wide. Recent electron
micrographic studies are beginning to reveal the precise three-
dimensional organization of the PSD and its constituent
protein complexes [20]. PSDs are composed primarily of
glutamate receptors, ion channels, cell adhesion molecules,
and signaling enzymes, as well as membrane trafficking,
cytoskeletal, and scaffolding proteins [11]. Key among these
are NMDA and AMPA receptors, PSD-95, Ca2+/calmodulin-
dependent kinase II (CamKII), NLGN, Shank family proteins,
synapse-associated protein-associated protein (SAPAP),
and actin. The PSD functions primarily as a postsynaptic
organizing structure—it clusters receptors, adhesion mole-
cules, and channels and assembles a variety of signaling
molecules at the postsynaptic membrane [21, 22].
Glutamate receptors and PSD proteins play a central role
in excitatory synaptic plasticity. Current models show that
intense NMDA receptor activation triggers a signaling
cascade in the PSD that induces recruitment of AMPA
receptors into the postsynaptic membrane, leading to long-
term potentiation (LTP) of synaptic strength, whereas
weaker prolonged activation of NMDA receptors leads to
removal of postsynaptic AMPA receptors and hence long-
term depression (LTD) [17]. Thus, it is of key importance
that the trafficking of synaptic AMPA receptors is controlled
carefully to modify synaptic strength during plasticity.
Misregulation of synaptic trafficking may contribute to
various brain disorders by preventing appropriate synaptic
signaling and plasticity [9].
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Spine Morphology Controls Synaptic Function
Dendritic spines are small membranous protrusions that
contain the postsynaptic machinery, including glutamate
receptors, the PSD, the actin cytoskeleton, and a wide
variety of membrane-bound organelles, such as smooth
endoplasmic reticulum, mitochondria, and endosomes
(Fig. 1) [11]. Typical spines have a bulbous head connected
to the dendritic shaft through a thin spine neck. Electron
microscopy studies identified several categories of spines
based on their shape and size: thin, stubby, cup, and
mushroom shaped [10]. Live imaging studies showed that
spines are remarkably dynamic, changing size and shape
over timescales of seconds to minutes and of hours to days
[23]. Dynamic changes in spine morphology are closely
linked to changes in strength of synaptic connections [1].
Mushroom spines have larger, more complex PSDs with a
higher density of glutamate receptors and are more sensitive
to glutamate [24]. The size of the spine head is correlated
with the dimensions of the PSD and the size of the
presynaptic active zone [10].
Spine morphology is subject to rapid alteration depend-
ing on neuronal activity and glutamate receptor activation.
Induction of LTP causes enlargement of spine heads,
whereas activity patterns that induce LTD cause spine head
shrinkage (Fig. 1) [1, 24]. Long-term in vivo two-photon
fluorescence imaging showed that dendritic spines undergo
structural changes in size and shape after novel sensory
experience [23]. Interestingly, abnormal spine structures
often are associated with various neurologic disorders, such
as fragile X syndrome (FXS), Rett’s syndrome, and Down
syndrome [9].
Recent studies have identified several cell biological
pathways that regulate dendritic spine morphology [25, 26].
Trafficking of recycling endosomes (REs) by motor protein
myosin Vb (MyoVb) leads to spine enlargement [27••, 28].
Transient invasion of dynamic microtubule into dendritic
spines is associated with the formation of spine head
protrusions and rapid spine growth [29••, 30]. Most
signaling pathways controlling spine shape seem to directly
or indirectly regulate the actin cytoskeleton [25, 26].
Therefore, it is not surprising that several genes that encode
factors involved in spine structure and organization have
been found mutated in human brain disease. GTPase-
activating proteins and guanosine exchange factors are
mutated in individuals with mental retardation and autism
[31]. LIM kinase 1, a serine/threonine kinase controlling
actin dynamics, and CYLN2, encoding for the microtubule
plus-end binding protein CLIP-115, are hemizygously
deleted in Williams-Beuren syndrome (WBS), leading to
abnormal thin spines, mental retardation, and visuospatial
cognitive deficits [32]. Consequently, there now is consid-
erable interest in understanding the underlying molecular
mechanisms of spine pathology and the relationship between
spine alterations and cognitive deficits.
Neuropsychiatric Disorders and Synapse Alteration
Neurodegenerative diseases, such as AD, Parkinson’s disease,
and Huntington’s disease, are caused by gradual neuronal
death, leading to decline in movement control, memory, and
cognition. The role of synaptic pathology in AD is particularly
interesting because β-amyloid (Aβ) oligomers, which are
formed after proteolytic cleavage of the amyloid precursor
protein (APP) may interfere with basic synaptic mechanisms
at an early disease stage [6, 33]. Moreover, alterations in
synaptic receptor trafficking, abnormal spine morphology,
and defects in synaptic function have been reported in
animal models of neuropsychiatric disorders including
addiction and schizophrenia [8, 34], as well as in models
of mental retardation, such as FXS [35]. Recently, autism
was associated with mutations in synaptic adhesion and
scaffolding molecules, which most likely have important
consequences for E/I balance [5]. Here, we discuss in more
detail the relationship between these disorders and synapse
pathology.
Autism Spectrum Disorders
Autism spectrum disorders (ASDs), including autism,
Asperger syndrome, and pervasive developmental disorder-
not otherwise specified, are diagnosed on the basis of three
behavioral features: deficits in social communication, absence
or delay in language, and stereotypy. ASDs are brain disorders
typically diagnosed before the second or third year of life,
during the time of human synapse formation and maturation
[36]. ASDs have a strong genetic basis and are the most
heritable (∼80%), suggesting that the disease is largely
determined by genes and not by the environment. Despite
the high heritability, the identification of genetic factors in
ASDs has proved difficult, at least partly because ASDs are
characterized by a high degree of genetic heterogeneity.
It has been widely speculated that alterations at the
synaptic level make individuals more vulnerable to devel-
oping ASDs. This theory was confirmed by the identification
of mutations affecting the synaptic cell adhesion molecules
NRXN and NLGN in individuals with ASD [37]. NRXNs
and NLGNs are thought to form a transsynaptic complex
stabilized by synaptic scaffolding proteins [5]. NRXNs are
presynaptic receptors, whereas NLGNs, the ligands of
NRXNs, are present on the postsynaptic side, where they
interact with PSD-95 and its binding partners, SAPAP and
Shank (Fig. 1). Mice lacking NRXNs or NLGNs show
strong deficits in synaptic transmission but not in synapse
number, suggesting that NRXNs and NLGNs are not
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required for the initial formation of synapses but are needed
for synaptic function [5]. Moreover, different members of the
NLGN family control the functional E/I balance in hippo-
campal neurons (Fig. 1).
The human genome contains three NRXN genes and
four NLGN genes. Several point mutations, distinct translo-
cation events, and different large-scale deletions in NRXN1,
NLGN3, and NLGN4 were observed in patients with autism
[37]. In addition, several mutations in the gene encoding
Shank3 have been found in patients with ASDs. However,
Shank3 mutations often are observed in nonsymptomatic
siblings, suggesting that Shank3 might only increase the
chance of ASDs rather than causing it [5]. Functional studies
of the NLGN3-R451C knock-in mice, which mimic a human
autistic mutation, showed enhanced spatial learning and
impaired social interaction. These mice exhibited a shift of
E/I balance by a selective enhancement of GABAA receptor-
mediated inhibitory synaptic transmission [38••]. Interestingly,
epilepsy, which also is caused by an imbalance between
excitatory and inhibitory synaptic transmission, is observed in
patients with autism.
These NRXN, NLGN, and Shank3 mutations still concern
a limited number of cases (<1% of individuals), but mutations
in other synaptic proteins, such as contactin-associated
protein-like 2 gene (CNTNAP2) and calcium channel
voltage-dependent L-type α1C subunit gene (CACNA1C),
were identified in patients with ASD-related syndromes [37].
Moreover, single nucleotide polymorphisms surrounding
several prominent ASD candidate loci, including NMDA
receptor (GRIN2A), kainate receptor (GRIK2), and cell
adhesion molecule cadherin 9/10 (CDH9/10) genes, were
identified as risk factors for ASD [39]. Overall, these
linkage, association, and functional studies suggest that
synaptic dysfunction most likely is the common defect in
ASDs.
Mental Retardation: Fragile X Syndrome
FXS, the most common inherited form of mental retarda-
tion, affecting approximately 1 in 4,000 males and 1 in
8,000 females, is characterized by reduced intellectual
ability, hyperactivity, hypersensitivity to sensory stimuli,
anxiety, impaired visuospatial processing, and developmental
delay. Thirty percent of children with FXS are diagnosed with
autism, and 2% to 5% of autistic children have FXS [40]. A
trinucleotide (CGG) repeat expansion, inactivating the
FMR1 gene on the X chromosome, leads to the absence of
the fragile X mental retardation protein (FMRP), resulting
in FXS [41]. The full mutation state is defined as more
than 200 CGG repeats in the 5′ untranslated region of the
FMR1 gene. Studies in patients and animal models of FXS
have identified marked alterations in dendritic spine mor-
phology [2]. Several studies report abnormally long, thin,
and immature filopodia-like spines, which are indicative of
alterations in synapse development and/or function in FXS.
In normal individuals, FMRP regulates the local process-
ing of a subset of mRNAs—transport, translation, and
stability—in response to activation of metabotropic glutamate
receptors (mGluRs) [42]. FMRP binds to several dendriti-
cally localized mRNAs that encode synaptic proteins, such
as PSD-95, activity-regulated cytoskeletal protein, elonga-
tion factor 1a, SAPAP3/4, AMPA receptor subunit GluR1/2,
and CamKIIα, which is consistent with the observed synapse
alterations in FXS [42]. Remarkably, many of the synapse
and behavioral deficits are rescued by reduced mGluR5
function [35]. Experimental evidence shows that AMPA
receptor internalization triggered by mGluR5 stimulation
is increased in FMRP knockout mice. It is tempting to
speculate that FMRP inhibits the translation of mRNAs that
are important for AMPA receptor trafficking, which might
explain the observed increase in LTD and excess of filopodia-
like spines in FXS. The potential link between the dysregu-
lation PSD-95 mRNA in FXS and LTD, is of especially great
interest [43•].
Neurodegenerative Disease: Alzheimer’s Disease
AD, the most common cause of dementia, is characterized
by early memory deficits, followed by the gradual decline
of cognitive and intellectual functions. Generally, it is diag-
nosed in people over 65 years of age, although early-onset
AD may occur [33]. In familial AD, autosomal dominant
mutations have been identified in the APP gene as well as
in genes encoding for presenilin 1 and 2, components of the
proteolytic-γ-secretase complex. AD is characterized by
loss of neurons and synapses in the hippocampus, cerebral
cortex, and subcortical regions, as well as Aβ plaques and
neurofibrillary lesions. The major protein component of
plaques is the polypeptide Aβ derived from proteolytic
cleavage of APP. Consistently, mutations linked to early-onset
familial AD lead to increased Aβ production. Importantly, Aβ
isolated directly from human AD brains can cause impaired
synaptic plasticity and memory in rodents [44•]. Synaptic
activity and chronic sleep restriction significantly increase
the amount of Aβ in brain interstitial fluid and plaque
formation in APP transgenic mice [45]. Mechanistically, Aβ
is thought to mediate toxicity by triggering signaling
cascades on the postsynaptic membrane. Neuronal culture
experiments revealed that surface APP is internalized by
clathrin-mediated endocytosis and that proteolytic Aβ
cleavage occurs in the endosomal pathway in the axon.
Subsequently, Aβ recycles to the cell surface, where it is
released into the extracellular fluid and triggers signaling
cascades on the postsynaptic membrane, sharing remarkable
similarities with LTD, including increased synaptic AMPA
receptor endocytosis and dendritic spine loss [46]. Recent
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studies showed that inhibition of endocytosis reduces APP
internalization and immediately lowers Aβ levels in vivo
[47•]. Thus, it is tempting to speculate that in its early stages,
AD is a disorder of synaptic receptor trafficking and synapse
dysfunction.
Addiction
Drug addiction, a chronic neuropsychiatric pathologic
condition caused, in part, by powerful and long-lasting
memories of the drug experience, has genetic, psychosocial,
and environmental dimensions. Generally, it is thought that
synaptic plasticity mechanisms normally used to reinforce
associated behavior become pathologic in patients with
drug addiction. Several in vivo studies indicate that
addictive drugs, such as cocaine, nicotine, and ethanol,
influence synaptic plasticity mechanisms in brain circuits
involved in reinforcement and reward processing [48].
Although modifications at the synaptic level are complex,
the current model suggests that addictive drugs might
induce LTP in the reward system. For instance, administra-
tion of cocaine elicits NMDA-dependent LTP at excitatory
synapses in the dopamine system [8]. Consistently, changes
in dendritic spine and synaptic proteins have been described
after chronic drug administration. An increase in dendritic
spine density and larger spine heads have been observed in
the striatum and prefrontal cortex of rats after 45 min of
acute cocaine administration to those withdrawn earlier
from chronic cocaine exposure [48]. Recent data show that
several synaptic mechanisms, such as AMPA receptor
trafficking, mGluR signaling, and spine actin dynamics, are
affected after chronic drug administration [8]. Interestingly,
exposure to cocaine generates inactive or “silent” synapses
[49•]. Reversing or preventing drug-induced synaptic mod-
ifications might provide treatments for drug addiction.
Conclusions
In recent years, genetic linkage studies have identified
several synaptic genes contributing to neuropsychiatric
disorders [6, 37, 41, 50]. At the same time, basic
neurobiological research has led to a better understanding
of the molecular composition, structure, and function of
synapses (Fig. 1) [11]. Novel pathways upstream of the
synapse have been discovered in which failure of the cellular
machinery leads to synaptic dysfunction and neuropsychiat-
ric phenotypes. Small non-coding microRNAs that repress
the translation of target mRNAs are emerging as important
pathophysiologic mechanisms for neurologic and psychiatric
disease. Abnormal regulation of protein turnover, chromatin
remodeling, and genomic imprinting also are suggested to
result in synapse pathology [50]. For instance, the gene
responsible for Angelman syndrome encodes for ubiquitin-
protein ligase E3A (UBE3A) and marks synaptic proteins for
degradation. The gene causing Rett syndrome encodes for
X-linked gene encoding methyl-CpG-binding protein 2
(MECP2) and is thought to modulate the expression of
synaptic activity-regulated genes, such as brain-derived
neurotrophic factor (BDNF).
In some cases, such as in FXS, the basic neurobiological
mechanisms underlying the symptoms are well studied and
become more clear, but in other cases, the pathways are
only beginning to be elucidated. Loss of function of a
single gene in FXS [41] or a limited number of genes in
WBS [32] provides a unique opportunity to uncover basic
neurobiological mechanisms underlying neuropsychiatric
diseases. Unfortunately, this model does not account for the
common forms of most neuropsychiatric disorders, which
are etiologically heterogeneous and complex and likely
determined by the combination of variants and/or defects in
multiple genes, each having a small effect. For example,
genome-wide association studies recently identified poly-
morphic variants in genes encoding synaptic proteins as
important determinants of the risk of developing ASD [39].
Other studies have implied that the genetic factors
between neuropsychiatric disorders may not be as diverse
as the clinical manifestations. It is not unlikely that an
alteration in the same gene may be associated with different
phenotypes in different people: one genetic alteration might
cause psychosis in one individual, obsessive-compulsive
disorder in another, and autism in yet another. Almost
certainly, these neuropsychiatric phenotypes are modified
by the genetic background and experiences throughout life.
It therefore is very likely that many disorders that involve
synapse dysfunction manifest in different ways. Conversely,
different mutations can produce similar syndromes. For
example, mutations in several different genes encoding for
proteins regulating the E/I synaptic balance have been linked
to epilepsy [18].
Neuropsychiatric diseases nicely illustrate the impor-
tance of synapse-specific molecules for normal synapse
composition and plasticity. To gain better insight into how
synapse pathology underlies psychiatric and neurologic
disease, it is essential to combine basic research with
clinical genetic studies. In this way, knowledge about
synapse function at the basic level has an immediate and
significant impact on clinically relevant issues. Finally,
synaptic molecules also are important future targets for
protective treatments, to slow disease progression and
preserve cognitive and functional abilities by preserving
synaptic structure and function.
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